$51.16
+5.05%Nov 3, 2026, 23:23 UTC
Alamar Biosciences, Inc. said it will collaborate with GSK plc using Alamar’s Nulisa platform to study circulating protein signatures and their relationship to disease progression, biological subtypes and treatment response across several disease areas.
Source:Nov 3, 2026, 09:15 UTC
Centrica Plc shares gained 2.50% to 153.65 pence, while Imperial Brands Plc, Tesco Plc, British American Tobacco p.l.c., GSK plc and DIAGEO PLC also rose.
Source:Oct 28, 2026, 15:45 UTC
GSK plc reported third-quarter adjusted earnings of $1.47 per share, or 54.6 pence, while specialty-drug sales grew by double digits and vaccine sales declined.
Source:Oct 28, 2026, 12:11 UTC
GSK plc reported quarterly earnings of $1.47 per share, above the Zacks Consensus Estimate of $1.40 and compared with $1.48 per share a year earlier.
Oct 28, 2026, 11:29 UTC
GSK plc shares fell after weaker vaccine sales were reported.
Oct 26, 2026, 16:20 UTC
GSK plc unveiled initial data from a global study of a next-generation chemotherapy.
Source:Oct 26, 2026, 16:20 UTC
A GSK plc cancer drug received approval for an additional tumor type.
Source:Oct 24, 2026, 00:29 UTC
GSK plc reported that its Morez therapy achieved median progression-free survival of 11.1 months in patients with platinum-resistant ovarian cancer, with a confirmed objective response rate of 62% and median duration of response of 12.2 months in an ovarian cancer trial.
Source:Oct 21, 2026, 12:37 UTC
US regulators approved GSK plc’s hepatitis B treatment Hibsago.
Oct 21, 2026, 00:58 UTC
Hutchison MediPharma (Shanghai) expects to receive a $110 million upfront payment from a GSK plc subsidiary in the near term under the completed HMPL-A830 licensing agreement.
Source:Oct 21, 2026, 00:05 UTC
HUTCHMED (China) Ltd. announced that its subsidiary HUTCHMED (China) Ltd. and a GSK plc subsidiary completed an exclusive development and licensing agreement for HMPL-A830 outside mainland China, Hong Kong, Macau and Taiwan.
Oct 20, 2026, 20:04 UTC
The GSK plc approved GSK's hepatitis B drug, offering patients the chance to stop long-term treatment.
Source:Oct 19, 2026, 06:39 UTC
GSK plc reported early-stage trial results for risvutatug rezetecan, with confirmed responses in 11 of 18 patients at 8 mg/kg and seven of 22 patients at 6 mg/kg.
Source:Oct 18, 2026, 22:22 UTC
GSK plc reported that its B7-H3-targeted antibody-drug conjugate Ris-Rez achieved a 61% objective response rate in a lung cancer clinical trial.
Oct 15, 2026, 01:44 UTC
Chia Tai Tianqing said its strategic-cooperation product Bepirovirsen was selected for two oral presentations and eight poster presentations at the 2026 AASLD annual meeting.
Source:Oct 14, 2026, 11:38 UTC
Belgian Prime Minister Bart De Wever is set to meet GSK plc and its employees to discuss a restructuring plan.
Source:Oct 14, 2026, 08:18 UTC
GSK plc informed Belgian unions of a proposed workforce reduction expected to affect 1,217 positions, including 735 management and 482 administrative roles.
Oct 9, 2026, 18:10 UTC
GSK plc is expanding its facility in Upper Merion Township, Pennsylvania, with construction planned to begin in 2027.
Source:Oct 9, 2026, 18:09 UTC
GSK plc plans to invest more than $800 million in Pennsylvania to expand operations and create over 300 jobs.
Source:Oct 9, 2026, 12:01 UTC
Chai Discovery announced a collaboration with GSK plc following a successful wet-lab evaluation.
Source:Oct 8, 2026, 22:00 UTC
The UK government will announce a £48 million partnership with healthcare companies and charities to accelerate dementia research and development.
Oct 8, 2026, 22:00 UTC
The UK government will invest £33 million through the Dame Barbara Windsor Dementia Goals programme to support dementia research and clinical-trial recruitment.
Source:Oct 8, 2026, 11:38 UTC
GSK announced a partnership with Viola Davis to launch the “Shingles, actually” educational campaign for adults aged 50 and older.
Source:Sep 30, 2026, 11:30 UTC
GSK selected a siRNA program from Wave Life Sciences to transition to GSK for further development, triggering a milestone payment to Wave, with three additional collaboration programs advancing.
Source:Sep 28, 2026, 08:45 UTC
A vaccinology training programme was launched on September 25 in Ho Chi Minh City, Vietnam, involving 10 specialities and training units to strengthen preventive healthcare capacity.
Source:Sep 24, 2026, 12:03 UTC
GSK announced that its AZUR-1 trial met its primary endpoint, achieving meaningful sustained clinical complete response at 12 months.
Source:Sep 21, 2026, 20:15 UTC
AnaptysBio, Inc. reported its financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.
Source:Sep 21, 2026, 10:45 UTC
Virbac Animal Health India marked 20 years of operations in India, growing from a Rs 100 crore business with about 200 employees to a consolidated turnover of Rs 1,650 crore with more than 1,600 employees.
Source:Sep 15, 2026, 07:58 UTC
GSK agreed to acquire global rights to a trispecific T-cell engager from China's Chimagen Biosciences for up to $750 million, with the drug to be developed for multiple myeloma and a Phase I trial planned for 2027.
Sep 14, 2026, 05:30 UTC
GSK is providing financial sponsorship for an HKU-led study and investing in shared data infrastructure to use Greater Bay Area patient data for healthcare policy and regulatory evidence.
Source:Sep 14, 2026, 00:37 UTC
GlaxoSmithKline announced that its drug Jideytro achieved a 94% objective response rate in previously untreated ROS1-positive non-small cell lung cancer patients in the registrational Phase I/II ARROS-1 trial.
Source:Jul 28, 2026, 10:17 UTC
GSK and Hansoh Pharmaceutical announced that their experimental drug Ris-Rez met the primary endpoint of progression-free survival in a late-stage trial for bone cancer.
Source:
Page 1Next →